Phase IIB , Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID ‐19
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70214 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Ruben Jara Rubio und 38 weiteren Autor:innen. Beteiligte Einrichtung: Intensive Care Service, University Hospital Virgen de la Arrixaca, IMIB-Pascual Parrilla, University of Murcia, Murcia, Spain. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Drug Treatment, Cytokine Release Syndrome, Fibrinolytic Agents. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jazz Pharmaceuticals, Instituto de Salud Carlos III, Paula and Rodger Riney Multiple Myeloma Research Fund.
Abstract (Originalsprache)
Introduction
Endothelial dysfunction is key in COVID‐19 pathogenesis. This randomized, double‐blind phase IIb trial investigated continuous intravenous infusion of defibrotide in patients hospitalized with SARS‐CoV‐2 infection and respiratory failure.
Methods
One‐hundred and fifty patients were randomized (2:1) to defibrotide or placebo, stratified by disease severity (WHO COVID‐19 severity scale 4/5 vs. 6). The primary endpoint was clinical improvement time (days from first improvement through Day 30).
Results
Median clinical improvement time was not significantly different with defibrotide versus placebo (15.0 [IQR: 0–24] vs. 20.0 [IQR: 9–25] days; p = 0.10). Day‐30 (23.0% vs. 22.0%) and Day‐60 (26.0% vs. 22.0%) mortality, reduction in mean fraction of inspired oxygen during treatment, and median duration of hospitalization did not differ with defibrotide versus placebo. Defibrotide demonstrated favorable safety, with no differences versus placebo in serious adverse events (34.0% vs. 36.0%), hypotension (16.0% vs. 12.0%), or hemorrhage (13.0% vs. 8.0%). Exploratory pre‐specified biomarker analyses showed greater early d ‐dimer reduction and lymphocyte recovery with defibrotide, although these results require validation.
Conclusion
Continuous intravenous infusion of defibrotide was safe but did not improve clinical outcomes in severe COVID‐19. Further analyses will explore mechanistic actions and pharmacokinetics of defibrotide and the pathophysiology of endothelial dysfunction in COVID‐19. Trial Registration: EudraCT identifier: 2020‐001409‐21. Clinicaltrials.gov identifier: NCT04348383
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Intensive Care Service, University Hospital Virgen de la Arrixaca, IMIB-Pascual Parrilla, University of Murcia, Murcia, Spain.
- Hematology Department, University Hospital Virgen de la Arrixaca, IMIB-Pascual Parrilla, University of Murcia, Murcia, Spain.
- Preventive Medicine Department, University Hospital Virgen de la Arrixaca, IMIB-Pascual Parrilla, University of Murcia, Murcia, Spain.
- Department of Quantitative Methods, Faculty of Economics and Business, University of Murcia, Murcia, Spain.
- Internal Medicine Department, University Hospital Virgen de la Arrixaca, IMIB-Pascual Parrilla, University of Murcia, Murcia, Spain.
- Medical Intensive Care Unit, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.
ORCID-Profile: José G Clavel, Sonia Marín, David García-Bernal, Lee-Jen Wei, Paul G Richardson, José M Moraleda
Förderung
- Jazz Pharmaceuticals
- Instituto de Salud Carlos III
- Paula and Rodger Riney Multiple Myeloma Research Fund
- Fundación Seneca
- Fundación Séneca
Zitieren
APA
Jara Rubio, R., Martinez-Mellado, A. J., Kiwitt-Cárdenas, J., Clavel, J. G., García-Perez, B., Castro, P., Diaz-Ricart, M., Carrillo-Alcaraz, A., López-Bernús, A., Bernal Morell, E., Roura, A., Marín, S., Ruiz-López, F. J., Solana-Martinez, E., Martinez-Baño, D., Albacete Moreno, C. L., Andreu Soler, E., Tellez Santoyo, A., Fernández Méndez, S., …, & Moraleda, J. M. (2026). Phase IIB , Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID ‐19. European Journal of Haematology. https://doi.org/10.1111/ejh.70214
Vancouver
Jara Rubio R, Martinez-Mellado AJ, Kiwitt-Cárdenas J, Clavel JG, García-Perez B, Castro P, et al. Phase IIB , Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID ‐19. European Journal of Haematology. 2026. doi:10.1111/ejh.70214
BibTeX
@article{JaraRubio2026,
author = {Jara Rubio, Ruben and Martinez-Mellado, Antonio José and Kiwitt-Cárdenas, Jonathan and Clavel, José G and García-Perez, Bartolomé and Castro, Pedro and Diaz-Ricart, Maribel and Carrillo-Alcaraz, Andrés and López-Bernús, Amparo and Bernal Morell, Enrique and Roura, Aychel and Marín, Sonia and Ruiz-López, Francisco-José and Solana-Martinez, Elena and Martinez-Baño, Domingo and Albacete Moreno, Carlos L and Andreu Soler, Enriqueta and Tellez Santoyo, Adrián and Fernández Méndez, Sara and Noguera Velasco, Jose A and Cebreiros Lopez, Iria and Parrilla, Andrés and Espuny-Miró, Alberto and García-Bernal, David and Blanquer, Miguel and Sánchez-Salinas, Andrés and Iniesta, Francisca and Hernandez Garcia, Cristina and Muro, Manuel and Minguela Puras, Alfredo and Moreno-Docón, Antonio and Torres-Cantero, Alberto M and Munoz Garcia, Maria and Serrano, Manuel and Iacobelli, Massimo and Carlo-Stella, Carmelo and Wei, Lee-Jen and Richardson, Paul G and Moraleda, José M},
title = {Phase IIB , Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID ‐19},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70214}
}
EUVIMED